A Phase 2 interventional study of LY2189265 and Placebo in Diabetes Mellitus, Type 2, sponsored by Eli Lilly and Company. Completed at 6 sites in Japan. Open to participants aged 20 Years to 75 Years. Per ClinicalTrials.gov, last updated 2015-09-28.
Sponsored by Eli Lilly and Company · Phase 2, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 54 studies testing dulaglutide in Diabetes Mellitus, Type 2 — 3 open to participants now, 4 under way, 1 of them phase 3. dulaglutide · Diabetes Mellitus, Type 2.
Among the 54 studies testing dulaglutide in Diabetes Mellitus, Type 2, this one is the 30th largest by enrollment, is the only one that started in 2009, is one of 5 in phase 2, and was the 4th registered.
10,386 studies on the registry are indexed under Diabetes Mellitus, Type 2; 1,411 are open to participants now.
Browse Diabetes Mellitus, Type 2 studies →3 of the 54 studies testing dulaglutide in Diabetes Mellitus, Type 2 are open now, in 3 countries. Recruiting first, the newest first:
Eli Lilly and Company · Sites in United States, Argentina, Mexico
Ages 10–17
First Affiliated Hospital of Wannan Medical College
Ages 18+
Seoul National University Bundang Hospital
Ages 20–90
By country, each count listing its studies:
dulaglutide: first FDA approval 2014 (TRULICITY), first EMA approval 2014. What it is approved for, and how studies give it, is on its page →
Of the 880 Diabetes Mellitus, Type 2 studies recruiting now, 374 (43%) set no upper age limit and 380 (43%) stop at 75 or younger; 52 take children under 18; 204 take healthy volunteers.
This study: 20 Years to 75 Years · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
54 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 15 · Phase 2 6 · Phase 3 23 · Phase 4 9
First in 2008; this study’s year is marked. 1 started in 2009.
By drug class, each counting the studies that test any of its medicines:
This study's enrollment of 145 is above the median of 80 across 8,361 interventional studies indexed under Diabetes Mellitus, Type 2.
Median enrollment 159 across the 54 interventional studies. Of the 47 that completed or were terminated, 38 (81%) have results posted.
This tab as a report to print or save as PDF → With an account.
45 of 54 have an industry lead sponsor. The 10 most frequent:
Eli Lilly and Company is the lead sponsor of 2,108 studies on the registry; 153 are open to participants now.
Of its 537 completed or terminated interventional studies of FDA-regulated products, 358 (67%) have results posted.
238 studies in Diabetes Mellitus, Type 2 by Eli Lilly and Company: 10 open now, 21 under way, 11 of them phase 3. Of 211 finished, 155 (73%) have results posted.
Among the 238 studies in Diabetes Mellitus, Type 2 by Eli Lilly and Company, this one is the 126th largest by enrollment of the 232 interventional ones that give a count, is one of 7 that started in 2009, is one of 34 in phase 2, and was the 39th registered.
Eli Lilly and Company’s Diabetes Mellitus, Type 2 studies by the year they started, since 2001.
1 of the studies testing dulaglutide in Diabetes Mellitus, Type 2 that are under way reach primary completion within a year, 0 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT07537088First Affiliated Hospital of Wannan Medical CollegeEfficacy and Safety of Triple Therapy With Dulaglutide, SGLT2 Inhibitors, and Finerenone in Chinese Adults With Type 2 Diabetes and Chronic Kidney Disease | 2027-04 |
Add it to your calendar (.ics) → With an account.
Among the 54 studies testing dulaglutide in Diabetes Mellitus, Type 2, from their registry updates:
Nothing recorded among them since 2026-09-25.
Among Eli Lilly and Company’s 238 in Diabetes Mellitus, Type 2:
This tab as a report to print or save as PDF → With an account.
The main purpose of this study is to assess dose-response characteristics in Japanese patients with Type 2 Diabetes taking LY2189265 monotherapy.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.
What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.
The protein in red blood cells that carries oxygen. A low level is anemia, which can cause tiredness and breathlessness. Measured in g/dL or g/L (9 g/dL is 90 g/L).
A blood test of average blood sugar over the past two to three months, given as a percentage or in mmol/mol. 6.5% (48 mmol/mol) or more is the usual threshold for diabetes, normally confirmed by a second test.
Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.
Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.
Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.
BMI (body mass index)
Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.
What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Hemoglobin (Hb)
The protein in red blood cells that carries oxygen. A low level is anemia, which can cause tiredness and breathlessness. Measured in g/dL or g/L (9 g/dL is 90 g/L).
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
HbA1c
A blood test of average blood sugar over the past two to three months, given as a percentage or in mmol/mol. 6.5% (48 mmol/mol) or more is the usual threshold for diabetes, normally confirmed by a second test.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Corticosteroids (steroids)
Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.
Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Clinically significant
Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Drug: LY2189265
Drug: LY2189265
Drug: LY2189265
Drug: Placebo
Administered by subcutaneous (SC) injection, once weekly (QW) for 12 weeks.
Administered by SC injection, QW for 12 weeks.
Change From Baseline in Glycosylated Hemoglobin (HbA1c) at 12 Weeks
Change in HbA1c from baseline following 12 weeks of therapy (that is, HbA1c at week 12 minus HbA1c at baseline). Changes in HbA1c were analyzed by a mixed model repeated measures (MMRM) model that included dose, pre-study therapy, body mass index (BMI) group at baseline, baseline value, visit, and dose\*visit, where the participant was treated as a random effect.
Time frame: Baseline, 12 weeks
Percentage of Participants Achieving Glycosylated Hemoglobin (HbA1c)<7% up to 12 Weeks
Percentage of participants who achieved HbA1c\<7% up to the 12-week endpoint.
Time frame: up to 12 weeks
Percentage of Participants Achieving Glycosylated Hemoglobin (HbA1c)<6.5% up to 12 Weeks
Percentage of participants achieving HbA1c\<6.5% up to the 12-week endpoint.
Time frame: up to 12 weeks
Change From Baseline in Fasting Blood Glucose (FBG) Values to 12 Weeks
Change in FBG following 12 weeks of therapy (that is, FBG at week 12 minus FBG at baseline). The change in FBG was analyzed using a mixed model repeated measures (MMRM) model that included dose, pre-study therapy, body mass index (BMI) group at baseline, baseline value, visit, and dose\*visit, where the participant was treated as a random effect.
Time frame: Baseline, 12 weeks
Change From Baseline in the Mean Daily Blood Glucose (Based on Self-Monitoring Blood Glucose [SMBG]) at 12 Weeks
SMBG levels were measured at the following 7 timepoints during the day: fasting prebreakfast, 2 hours postbreakfast, prior to lunch, 2 hours postlunch, prior to dinner, 2 hours postdinner, and prior to bed. The change in mean daily blood glucose was analyzed by a mixed model repeated measures (MMRM) model that included dose, pre-study therapy, body mass index (BMI) group at baseline, baseline value, and dose\*visit, where the participant was treated as a random effect.
Time frame: Baseline, 12 weeks
Change From Baseline in Total Body Weight at 12 Weeks
Changes in body weight were analyzed by a mixed model repeated measures (MMRM) model that included dose, pre-study therapy, body mass index (BMI) group at baseline, baseline value, visit, and dose\*visit, where the participant was treated as a random effect.
Time frame: Baseline, 12 weeks
Change From Baseline in Insulin Sensitivity Using the Updated Homeostasis Model Assessment Insulin Sensitivity (HOMA2-S) at 12 Weeks
HOMA2-S is an estimated insulin sensitivity based on updated HOMA2 model. The HOMA2 model is a computer model that estimates insulin sensitivity (%S) as percentages of a normal reference population using simultaneously measured fasting plasma glucose and fasting insulin. Changes in HOMA2-S were analyzed by a mixed model repeated measures (MMRM) model that included dose, pre-study therapy, body mass index (BMI) group at baseline, baseline value, visit, and dose\*visit, where the participant was treated as a random effect.
Time frame: Baseline, 12 weeks
Change From Baseline in Beta-Cell Function Using the Updated Homeostasis Model Assessment Beta-Cell Function (HOMA2-B) at 12 Weeks
HOMA2-B is an estimated steady state beta cell function based on updated HOMA2 model. The HOMA2 model estimates steady state pancreatic beta cell function (%B) as a percentage of a normal reference population using simultaneously measured fasting plasma glucose and fasting insulin. Changes in HOMA2-B were analyzed by a mixed model repeated measures (MMRM) model that included dose, pre-study therapy, body mass index (BMI) group at baseline, baseline value, visit, and dose\*visit, where the participant was treated as a random effect.
Time frame: Baseline, 12 weeks
Steady-State Concentrations of LY2189265
Evaluable pharmacokinetics (PK) concentrations from all sampling time-points were combined and utilized in a population approach to determine the population mean estimate and standard deviation at 12 weeks. The model predicted LY2189265 steady state concentrations in each dose level were calculated as estimated area under the curve (AUC)/dosing period of 168 hours. The models and model parameters were described by nonlinear, mixed-effects regression modeling (NONMEM) using the program NONMEM 7®.
Time frame: 12 weeks
Percentage of Participants With Self-Reported Hypoglycemic Episodes During the 12-week Treatment Period
Assessed the percentage of participants who reported a hypoglycemic episode during the 12-week treatment period. Hypoglycemia was defined as a measured plasma glucose level of ≤70 milligrams per deciliter (mg/dL) or ≤3.9 millimoles per liter (mmol/L).
Time frame: 12 weeks
| Milestone | 0.75 mg LY2189265 | 0.5 mg LY2189265 | 0.25 mg LY2189265 | Placebo |
|---|---|---|---|---|
| Started | 35 | 37 | 36 | 37 |
| Completed | 33 | 36 | 35 | 34 |
| Not completed | 2 | 1 | 1 | 3 |
| Withdrew: Adverse event | 2 | 1 | 0 | 0 |
| Withdrew: Lost to follow-up | 0 | 0 | 1 | 0 |
| Withdrew: Entry criteria not met | 0 | 0 | 0 | 1 |
| Withdrew: Withdrawal by subject | 0 | 0 | 0 | 2 |
Change in HbA1c from baseline following 12 weeks of therapy (that is, HbA1c at week 12 minus HbA1c at baseline). Changes in HbA1c were analyzed by a mixed model repeated measures (MMRM) model that included dose, pre-study therapy, body mass index (BMI) group at baseline, baseline value, visit, and dose\*visit, where the participant was treated as a random effect.
| percentage glycosylated hemoglobin | 0.75 mg LY2189265 | 0.5 mg LY2189265 | 0.25 mg LY2189265 | Placebo |
|---|---|---|---|---|
| Change From Baseline in Glycosylated Hemoglobin (HbA1c) at 12 Weeks | -1.35 (-1.53 to -1.18) | -1.15 (-1.32 to -0.98) | -0.90 (-1.07 to -0.73) | -0.18 (-0.36 to -0.01) |
Percentage of participants who achieved HbA1c\<7% up to the 12-week endpoint.
| percentage of participants | 0.75 mg LY2189265 | 0.5 mg LY2189265 | 0.25 mg LY2189265 | Placebo |
|---|---|---|---|---|
| Percentage of Participants Achieving Glycosylated Hemoglobin (HbA1c)<7% up to 12 Weeks | 77.1 | 59.5 | 47.2 | 10.8 |
Percentage of participants achieving HbA1c\<6.5% up to the 12-week endpoint.
| percentage of participants | 0.75 mg LY2189265 | 0.5 mg LY2189265 | 0.25 mg LY2189265 | Placebo |
|---|---|---|---|---|
| Percentage of Participants Achieving Glycosylated Hemoglobin (HbA1c)<6.5% up to 12 Weeks | 34.3 | 24.3 | 8.3 | 2.7 |
Change in FBG following 12 weeks of therapy (that is, FBG at week 12 minus FBG at baseline). The change in FBG was analyzed using a mixed model repeated measures (MMRM) model that included dose, pre-study therapy, body mass index (BMI) group at baseline, baseline value, visit, and dose\*visit, where the participant was treated as a random effect.
| milligrams per deciliter (mg/dL) | 0.75 mg LY2189265 | 0.5 mg LY2189265 | 0.25 mg LY2189265 | Placebo |
|---|---|---|---|---|
| Change From Baseline in Fasting Blood Glucose (FBG) Values to 12 Weeks | -37.48 (-47.00 to -27.97) | -28.55 (-37.68 to -19.41) | -29.21 (-38.45 to -19.97) | -9.00 (-18.39 to 0.38) |
SMBG levels were measured at the following 7 timepoints during the day: fasting prebreakfast, 2 hours postbreakfast, prior to lunch, 2 hours postlunch, prior to dinner, 2 hours postdinner, and prior to bed. The change in mean daily blood glucose was analyzed by a mixed model repeated measures (MMRM) model that included dose, pre-study therapy, body mass index (BMI) group at baseline, baseline value, and dose\*visit, where the participant was treated as a random effect.
| milligrams per deciliter (mg/dL) | 0.75 mg LY2189265 | 0.5 mg LY2189265 | 0.25 mg LY2189265 | Placebo |
|---|---|---|---|---|
| Change From Baseline in the Mean Daily Blood Glucose (Based on Self-Monitoring Blood Glucose [SMBG]) at 12 Weeks | -48.99 (-58.47 to -39.51) | -53.12 (-61.84 to -44.41) | -40.70 (-49.67 to -31.73) | -7.49 (-17.44 to 2.45) |
Changes in body weight were analyzed by a mixed model repeated measures (MMRM) model that included dose, pre-study therapy, body mass index (BMI) group at baseline, baseline value, visit, and dose\*visit, where the participant was treated as a random effect.
| kilograms (kg) | 0.75 mg LY2189265 | 0.5 mg LY2189265 | 0.25 mg LY2189265 | Placebo |
|---|---|---|---|---|
| Change From Baseline in Total Body Weight at 12 Weeks | -0.58 (-1.21 to 0.05) | -0.40 (-1.01 to 0.22) | 0.41 (-0.20 to 1.03) | -0.84 (-1.46 to -0.22) |
HOMA2-S is an estimated insulin sensitivity based on updated HOMA2 model. The HOMA2 model is a computer model that estimates insulin sensitivity (%S) as percentages of a normal reference population using simultaneously measured fasting plasma glucose and fasting insulin. Changes in HOMA2-S were analyzed by a mixed model repeated measures (MMRM) model that included dose, pre-study therapy, body mass index (BMI) group at baseline, baseline value, visit, and dose\*visit, where the participant was treated as a random effect.
| percentage insulin sensitivity (%S) | 0.75 mg LY2189265 | 0.5 mg LY2189265 | 0.25 mg LY2189265 | Placebo |
|---|---|---|---|---|
| Change From Baseline in Insulin Sensitivity Using the Updated Homeostasis Model Assessment Insulin Sensitivity (HOMA2-S) at 12 Weeks | -4.66 (-17.64 to 8.32) | -6.07 (-18.60 to 6.46) | 4.65 (-7.68 to 16.97) | 3.74 (-8.88 to 16.36) |
HOMA2-B is an estimated steady state beta cell function based on updated HOMA2 model. The HOMA2 model estimates steady state pancreatic beta cell function (%B) as a percentage of a normal reference population using simultaneously measured fasting plasma glucose and fasting insulin. Changes in HOMA2-B were analyzed by a mixed model repeated measures (MMRM) model that included dose, pre-study therapy, body mass index (BMI) group at baseline, baseline value, visit, and dose\*visit, where the participant was treated as a random effect.
| percentage beta-cell function | 0.75 mg LY2189265 | 0.5 mg LY2189265 | 0.25 mg LY2189265 | Placebo |
|---|---|---|---|---|
| Change From Baseline in Beta-Cell Function Using the Updated Homeostasis Model Assessment Beta-Cell Function (HOMA2-B) at 12 Weeks | 38.63 (29.36 to 47.90) | 26.67 (17.74 to 35.61) | 20.04 (11.19 to 28.89) | 6.94 (-2.10 to 15.98) |
Evaluable pharmacokinetics (PK) concentrations from all sampling time-points were combined and utilized in a population approach to determine the population mean estimate and standard deviation at 12 weeks. The model predicted LY2189265 steady state concentrations in each dose level were calculated as estimated area under the curve (AUC)/dosing period of 168 hours. The models and model parameters were described by nonlinear, mixed-effects regression modeling (NONMEM) using the program NONMEM 7®.
| nanograms per milliliter (ng/mL) | LY 0.25 mg | LY 0.50 mg | LY 0.75 mg |
|---|---|---|---|
| Steady-State Concentrations of LY2189265 | 15.8 (10.4 to 27.0) | 28.8 (19.2 to 47.4) | 42.7 (24.3 to 70.0) |
Assessed the percentage of participants who reported a hypoglycemic episode during the 12-week treatment period. Hypoglycemia was defined as a measured plasma glucose level of ≤70 milligrams per deciliter (mg/dL) or ≤3.9 millimoles per liter (mmol/L).
| percentage of participants | 0.75 mg LY2189265 | 0.5 mg LY2189265 | 0.25 mg LY2189265 | Placebo |
|---|---|---|---|---|
| Percentage of Participants With Self-Reported Hypoglycemic Episodes During the 12-week Treatment Period | 5.7 | 2.7 | 0.0 | 0.0 |
Non-serious events are listed at a 2% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| Placebo | — | 0/37 (0%) | 16/37 (43.2%) |
| 0.25 mg LY2189265 | — | 1/36 (2.8%) | 17/36 (47.2%) |
| 0.5 mg LY2189265 | — | 0/37 (0%) | 18/37 (48.6%) |
| 0.75 mg LY2189265 | — | 1/35 (2.9%) | 15/35 (42.9%) |
| Event | Placebo | 0.25 mg LY2189265 | 0.5 mg LY2189265 | 0.75 mg LY2189265 |
|---|---|---|---|---|
| Pancreatic carcinomaNeoplasms benign, malignant and unspecified (incl cysts and polyps) | 0/37 | 0/36 | 0/37 | 1/35 |
| VIIth nerve paralysisNervous system disorders | 0/37 | 1/36 | 0/37 | 0/35 |
| Event | Placebo | 0.25 mg LY2189265 | 0.5 mg LY2189265 | 0.75 mg LY2189265 |
|---|---|---|---|---|
| NauseaGastrointestinal disorders | 0/37 | 0/36 | 6/37 | 2/35 |
| NasopharyngitisInfections and infestations | 6/37 | 3/36 | 3/37 | 3/35 |
| ConstipationGastrointestinal disorders | 0/37 | 0/36 | 0/37 | 3/35 |
| HeadacheNervous system disorders | 1/37 | 0/36 | 3/37 | 0/35 |
| Seasonal allergyImmune system disorders | 1/37 | 2/36 | 0/37 | 2/35 |
| Blood triglycerides increasedInvestigations | 0/37 | 2/36 | 0/37 | 0/35 |
| Abdominal pain upperGastrointestinal disorders | 0/37 | 0/36 | 2/37 | 0/35 |
| DiarrhoeaGastrointestinal disorders | 2/37 | 1/36 | 1/37 | 1/35 |
| Abdominal discomfortGastrointestinal disorders | 0/37 | 1/36 | 1/37 | 1/35 |
| Abdominal distensionGastrointestinal disorders | 0/37 | 0/36 | 0/37 | 1/35 |
| Age, Continuous(years) | 0.75 mg LY2189265 | 0.5 mg LY2189265 | 0.25 mg LY2189265 | Placebo | Total |
|---|---|---|---|---|---|
| Mean | 52.23 ± 7.80 | 52.50 ± 9.17 | 52.26 ± 8.82 | 51.70 ± 9.67 | 52.17 ± 8.82 |
| Sex: Female, Male(Participants) | 0.75 mg LY2189265 | 0.5 mg LY2189265 | 0.25 mg LY2189265 | Placebo | Total |
|---|---|---|---|---|---|
| Female | 7 | 14 | 9 | 8 | 38 |
| Male | 28 | 23 | 27 | 29 | 107 |
| Race/Ethnicity, Customized(participants) | 0.75 mg LY2189265 | 0.5 mg LY2189265 | 0.25 mg LY2189265 | Placebo | Total |
|---|---|---|---|---|---|
| Japanese | 35 | 37 | 36 | 37 | 145 |
| Region of Enrollment(participants) | 0.75 mg LY2189265 | 0.5 mg LY2189265 | 0.25 mg LY2189265 | Placebo | Total |
|---|---|---|---|---|---|
| Japan | 35 | 37 | 36 | 37 | 145 |
| Percentage of Glycosylated Hemoglobin (HbA1c)(percentage of glycosylated hemoglobin) | 0.75 mg LY2189265 | 0.5 mg LY2189265 | 0.25 mg LY2189265 | Placebo | Total |
|---|---|---|---|---|---|
| Mean | 8.01 ± 0.63 | 7.98 ± 0.66 | 8.05 ± 0.66 | 7.98 ± 0.64 | 8.00 ± 0.64 |
| Fasting Blood Glucose (FBG)(milligrams per deciliter (mg/dL)) | 0.75 mg LY2189265 | 0.5 mg LY2189265 | 0.25 mg LY2189265 | Placebo | Total |
|---|---|---|---|---|---|
| Mean | 156.51 ± 26.43 | 150.95 ± 29.31 | 158.75 ± 35.62 | 159.65 ± 33.29 | 156.45 ± 31.26 |
The record gives a start of Oct 2009, a primary completion of Dec 2010 and a completion of Dec 2010. It does not say whether these dates are actual or estimated.
Results were first posted in Sep 2015, 4 years 9 months after primary completion. A results delay was requested in Apr 2011.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in Aug 2015. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: Dulaglutide